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PROGESTERONE IN LATE FOLLICULAR PHASE AND PREGNANCY RATES
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a case-controlled study in ICSI cycles
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Abstract
Objective: The aim of the presented study is to investigate the impact of progesterone change
in the late follicular phase on the pregnancy rates of both agonist and antagonist protocols in
normoresponders.
Study design: A total of 201 normoresponder patients, who underwent embryo transfer were
consecutively selected. 118 patients were stimulated using a long luteal GnRH agonist protocol
and 83 using a flexible antagonist protocol. The level of change in late follicular phase
progesterone was calculated according to the progesterone levels on the hCG day and pre-hCG
day (1 or 2 days prior to hCG day) measurement.
Results: Clinical pregnancy rates were comparable between long luteal and antagonist group
(35.6 and 41%, respectively). The incidence of progesterone elevation on the hCG day was 11%
in long luteal and 18% in antagonist group (p¼ 0.16). In pregnant cycles, p levels both on the
hCG day and pre-hCG day measurement were significantly higher in antagonist than agonist
cycles (p¼ 0.029, p¼ 0.038, respectively). The change of p level was statistically significant in
non-pregnant cycles both for the agonist (-0.17 ± 0.07; 95% CI:0.29 to0.37) and antagonist
groups (0.18 ± 0.07; 95%CI:0.31 to0.04).
Conclusions: Late follicular phase progesterone levels were stable during the cycles of pregnant
patients irrespective of the protocols and were shown to be higher in pregnant patients in
antagonist cycles when compared to agonist cycles.
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Introduction
The incidence of premature LH surge is significantly reduced
using GnRH analogs in in vitro fertilization (IVF) cycles [1].
Premature progesterone rise is a different entity, which can have
significant effects on in-vitro fertilization outcomes. Literature
about this topic demonstrates a wide range of incidences, varying
from 2 to 35% [2,3].
Progesterone rise has recently been associated with the number
of preovulatory follicles, which is excessive in number but each
produces a normal amount of progesterone for the late follicular
phase [4] and high E2 exposure [5,6]. Although late follicular
phase progesterone rise is often seen in women displaying a good
response to ovarian stimulation, it can also take place in poor
responders, hence through a different mechanism. These patients
need longer stimulation and thus a significantly higher total FSH
dose [7,8]. They may have an increased sensitivity to LH as
another mechanism [9].
Whatever the mechanism of progesterone increase in the late
follicular phase, progesterone exerts its detrimental effects
through its action on the endometrium [3,10,11]. High serum
progesterone levels on the day of HCG administration induce both
advanced endometrial histological maturation [12] and differen-
tial endometrial gene expression [13,14], which may lead to
implantation failure [2]. However, a single measurement during
the whole cycle has limited value and statistical evaluation of
multiple measurements throughout the cycle is a difficult issue.
Late follicular phase progesterone rise is an indicator of
granulosa cell function in normoresponder patients. The aim of
this study was to determine the effect of the change in late
follicular phase serum progesterone levels on cycle outcomes of
IVF/ET cycles in normoresponder patients undergoing either
GnRH agonist or antagonist cycles.
Methods
The present case control study was conducted in the IVF clinic of
Etlik Zubeyde Hanim Women’s Health Teaching and Research
Hospital, Ankara, Turkey, between January 2012 and June 2014.
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The inclusion criteria were as follows: (1) age535; (2) basal
FSH514 IU/ml; (3) body mass index (BMI), 18–25 kg/m2; (4)
antral follicle count47; (5) previous IVF cycles53; (6) ejaculated
sperm used for the ICSI procedure; (7) all patients who underwent
embryo transfer were selected consecutively. The study was
approved by the Institutional Review Board (20.12.2012/number
160-2). Written informed consent was obtained from all subjects
before their enrollment in the study.
Statistics of our clinic for the year 2014 showed that the
distribution rates of stimulation protocols used in normoresponder
patients was comparable (52 versus 48% for antagonists and
agonists, respectively). The GnRH-agonist long protocol was
begun in the mid-luteal phase of the previous cycle with
leuprolide acetate (Lucrin, Abbot, Turkey). After onset of
menstrual bleeding, when satisfactory pituitary desensitization
was achieved (serum E2 level550 pg/ml, endometrial thick-
ness55 mm, serum LH levels55 IU/ml), the GnRH agonist dose
was reduced to half and gonadotrophin administration was started
with daily use of recombinant FSH (Gonal-F; Merck Serono,
Istanbul, Turkey or Puregon, Organon, Istanbul, Turkey). Dose of
gonadotrophins was individualized according to the patient’s age,
baseline serum FSH concentration on day 3 and body mass index
(BMI). In the GnRH-antagonist protocol, gonadotrophins were
administered from day 2 of the cycle and co-treatment with a
GnRH antagonist, 0.25 mg ganirelix (MSD Organon, Oss, The
Netherlands) or 0.25 mg cetrorelix (Merck-Serono, Geneva,
Switzerland), was begun when the diameter of the follicle reached
12 mm or the E2 level was 250 pg/ml.
Cycles were monitored by means of serial transvaginal
ultrasound evaluation scans and serum determination of estradiol,
progesterone and LH. The level of change in late follicular phase
progesterone was calculated according to the progesterone levels
on the hCG day and pre-hCG day measurement. The pre-
measurement was conducted 1 or 2 days prior to hCG day. The
non-significant change in the late follicular phase progesteron was
accepted as stable change. The threshold level for progesterone
elevation was accepted as p42 ng/ml.
For both study groups, final oocyte maturation was induced
with the administration of rec-hCG (Ovitrelle; Merck-Serono,
Istanbul, Turkey) (250 mg when BMI529 kg/m2 and 500 mg when
BMI429 kg/m2) when at least three follicles of 17 mm were
present. Oocyte retrieval (OPU) was performed 35.5–36 h after
the administration of the rec-hCG preparation by transvaginal
ultrasound-guided aspiration.
The embryo evaluation and scoring was performed by using
appropriate scoring systems modified from previously described
systems [15,16]. Day 2 embryos were classified according to size,
nucleation and cytoplasmic morphology of blastomeres (percent-
age of anucleate fragments; cleavage speed and zona pellucida
thickness) 42–44 h after the insemination. On Day 3, embryos
were scored 64–65 h after insemination for cell number and
degree of fragmentation and cell size. Blastocyst stage embryo
scoring was performed based on the number of even-sized cells,
visible inner cell mass and continuous trophoectoderm with
sufficient cells. Embryos were classified from Grades 1 to 5 (best
to worst).
Luteal support was given by either vaginal progesterone
(Crinone 8% gel, Serono, Istanbul) twice a day or vaginal
progesterone plus 100 mg intramuscular progesterone from
embryo transfer to pregnancy test. Pregnancy was determined
by b-hCG levels in blood tests performed 12 days after embryo
transfer and clinical pregnancy was defined as the presence of a
gestational sac with accompanying fetal heartbeat.
Hormonal immunoassays
Serum samples were analyzed using Immulite 2000 reproductive
hormone assays (Diagnostic Product Corporation, Siemens, Los
Angeles, CA). The sensitivity was 0.1 mIu/ml for FSH; 0.05 mIu/
ml for LH; 15 pg/ml for E2 and 0.1 ng/ml for P. Intra-assay and
inter-assay coefficients of variation were53.6% and54.3% for
FSH;54.8% and510.7% for LH;56.7% and59.7% for E2
and59.7% and512.2% for P, respectively.
Statistical analysis
Statistical analyses were performed using the Statistical Package
for the Social Sciences (SPSS) Windows version 17.0 (SPSS Inc.,
Chicago, IL). Distribution of the continuous variables was
checked using the Kolmogorov-Smirnov test. Student’s t-test
was used for variables with normal distribution. After testing the
skewed distribution, comparisons between the groups were tested
using the Mann-Whitney U-test. The chi-square test was used to
analyze nominal variables. Continuous variables were expressed
as mean ± standard error (SE). The level of change in late
follicular phase progesterone was tested using paired samples t-
test or two-related samples test according to the variables
distribution. A value of p50.05 was accepted as statistically
significant.
Results
A total of 201 patients, 118 patients undergoing a long luteal
GnRH agonist protocol and 83 undergoing a flexible antagonist
protocol were enrolled in the study. The demographic charac-
teristics, progesterone levels and pregnancy rates of the groups
are presented in Table 1. Demographic characteristics were
comparable between the two groups (Table 1). Progesterone
levels during the stimulation cycle of the pregnant and non-
pregnant patients in antagonist and agonist cycles are shown in
Figure 1.
Clinical pregnancy rates were 35.6% in the long luteal group
and 41% in the antagonist group (p¼ 0.44). The incidence of
progesterone elevation in late follicular phase (42 ng/ml) was 11%
in the long luteal group and 18% in the antagonist group
(p¼ 0.16). There were no significant differences on the clinical
pregnancy rates according to the day of embryo transfer in
patients with and without embryo transfer (Table 2).
In pregnant cycles, P levels both on hCG day and pre-hCG day
measurement were significantly higher in antagonist cycles than
agonist cycles (p¼ 0.029 and p¼ 0.038, respectively) (Table 1).
When the level of changes of P between the hCG day and pre-
hCG day measurement was compared, no significant difference
was found in pregnant cycles for both the agonist and antagonist
groups. The change in P level was statistically significant in non-
pregnant cycles in both the agonist (0.17 ± 0.07; p: 0.013 CI
95%: 0.29 to 0.37) and antagonist groups (0.18 ± 0.07;
p: 0.011, CI 95%: 0.31 to 0.04) (Figure 1).
The comparison of pregnant and non-pregnant patients treated
with the antagonist protocol revealed that only the number of
good quality embryos was significantly higher in pregnant cycles
(p¼ 0.007). Progesterone levels on the hCG day and pre-hCG day
measurement were similar in pregnant and non-pregnant cycles
(Table 3).
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Figure 1. Means progesteron levels of pregnant and non-pregnant normo-responder patients in antagonist and long luteal cycles. *X axis: Progesteron
measurement step through the stimulation period (2nd, 4th, 6th), y axis: Mean progesteron level (ng/ml).
Table 1. Demographic features of the patients.
Long luteal (n¼118) Antagonist (n¼83) p Value 95% CI
Age (years) 28.2 ± 0.4 28.4 ± 0.4 0.72 1.27 to 0.90
BMI (kg/m2) 24.6 ± 0.3 23.5 ± 0.4 0.019* 0.17 to 2.03
Number of previous cycles 1.5 ± 0.8 1.7 ± 0.1 0.79 0.48 to 0.015
Baseline FSH (IU/ml) 7.1 ± 0.2 7.5 ± 0.2 0.31 0.99 to 0.13
Baseline LH (IU/ml) 5.2 ± 0.2 5.8 ± 0.4 0.33 1.448 to 0.21
Baseline E2 (pg/ml) 43.9 ± 2.1 44.2 ± 3 0.71 7.337 to 6.82
Duration of infertility (months) 66.7 ± 3.8 69.9 ± 5 0.61 15.38 to 9.017
AFC 15.8 ± 0.5 16 ± 0.7 0.84 1.908 to 1.538
TPSC (million) 31.931 ± 5880 27.081±5909 0.81 12 033.7 to 21 734.0
Number of top quality embryos 2.2 ± 0.2 2.5 ± 0.2 0.29
Rate of embryo cryopreservation 18.6 19.3 0.91
Number of embryos transferred 1 (1–2) 1 (1–2) 0.64
The day of embryo transfer (n, %)
Day 3 43 (36.4) 34 (41) 0.52
Day 5 75 (63.6) 49 (59)
Clinical pregnancy rate 35.6% 41% 0.44
Progesterone elevation rate (42.0 ng/ml) (n, %) 13 (11%) 15 (18.1%) 0.16
Progesterone levels in pregnant patients (ng/ml)
hCG day pre-measurement 1.11 ± 0.1 1.37 ± 0.1 0.038* 0.5 to 0.01
hCG day 1.24 ± 0.1 1.51 ± 0.1 0.029* 0.51 to 0.027
Progesterone levels in nonpregnant patients (ng/ml)
hCG day pre-measurement 1.19 ± 0.1 1.2 ± 0.1 0.67
hCG day 1.37 ± 0.1 1.38 ± 0.1 0.87
BMI, body mass index; FSH, follicle stimulating hormone; LH, luteinizing hormone; E2, estradiol; AFC, antral follicle count; TPMSC, total
progressive motile sperm count; P, progesterone.
*Statistically significant, data were presented as mean ± SE and n (%), n (%), median (minimum &unknown_hyphen; maximum).
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In agonist cycles, the number of top-quality embryos and
fertilization rates were found to be significantly higher in
pregnant patients than non-pregnant ones (p¼ 0.018 and
p¼ 0.003, respectively) (Table 4).
Discussion
The results of this study demonstrated that late follicular
phase progesterone levels were stable during the cycles of
pregnant patients irrespective of the protocol. Late follicular
phase progesterone levels were shown to be higher in
pregnant patients in antagonist cycles when compared to
agonist cycles. The number of top-quality embryos was the
most important factor that determined the clinical pregnancy
in both groups.
According to the two-cell two-gonadotrophin theory [17],
progesterone is produced by the conversion of pregnenolone
through the action of 3b-hydroxysteroid dehydrogenase (3bHSD)
in granulosa cells. It is then transported to the theca cells, where it
is metabolized into androgens and eventually to estrogen through
the activity of C17 hydroxylase present only in theca cells.
Progesterone is an intermediate product in the estrogen produc-
tion pathway. During the early follicular phase, LH acts exclu-
sively on theca cells to stimulate both 3bHSD and C17
hydroxylase in a balanced manner. However, during the late
follicular phase, LH acts not only on theca cells but also its action
on granulosa cells becomes evident with the expression of an
increasing number of LH receptors on granulosa cells of growing
follicles. With the addition of the stimulatory effect of LH on
3bHSD in granulosa cells, they become another source of
increasing progesterone production. In this steroidogenic pathway,
estrogen is the end product while progesterone is the intermediate
one. Therefore, progesterone measured during the late follicular
phase reflects the function of the mature and growing mass of
granulosa cells [18].
The detrimental effect of late follicular phase progesterone
elevation is thought to be exerted through action on the
endometrium [3,10,11,19,20]. However, there are still questions
regarding its mechanism of action. The late follicular phase
progesterone rise produces an asynchrony between endometrial
maturation and the embryo, which eventually causes a reduction
in implantation rates. Endometrial gene expression studies
provide more direct evidence about the effects of progesterone
on the endometrium. Two recent studies reported that when serum
progesterone at the time of hCG administration is41.5 ng/ml, the
gene expression profile is modified and expression of more than
100 genes is significantly dysregulated [13,14], genes that are
implicated in cell adhesion, developmental processes or the
immune system. However, different cut-off values determined for
high, normo and poor responders suggest that different mechan-
isms other than endometrial advancement could have a potential
role in its detrimental effects on IVF outcome. Otherwise, a single
threshold value would be sufficient to explain its effects in all
groups.
Another mechanism, other than the progesterone rise in the
single progesterone measurement, might be the duration of the
late follicular phase progesterone elevation. Huang et al. [21]
studied 1784 patients undergoing IVF/ICSI cycles retrospectively
and grouped the patients according to the duration of progesterone
elevation during the follicular phase, defined as41.0 ng/ml. They
demonstrated that the clinical pregnancy rate was significantly
decreased in women with longer elevated serum P levels,
independent of the protocol used and the ovarian response. It
has been suggested that a single determination of serum
progesterone on the day of hCG could be less informative than
Table 4. Controlled ovarian stimulation characteristics of pregnant and non-pregnant normo-responder patients in long agonist cycles.
Pregnant (n¼42) Non-pregnant (n¼76) p Value 95%CI
P on the day hCG day pre-measurement (ng/ml) 1.11 ± 0.07 1.19 ± 0.06 0.43 0.1 to 0.279
P on the hCG day (ng/ml) 1.25 ± 0.07 1.37 ± 0.07 0.55 0.09 to 0.337
E2 on the hCG day (pg/ml) 3486.1 ± 241.6 3740.88 ± 252.8 0.90 507.6 to 1017.1
Number of retrieved oocytes 15.7 ± 1.2 17 ± 1 0.53 1.95 to 4.65
Number of MII oocytes 11.7 ± 0.71 11.9 ± 0.8 0.68 2.21 to 2.65
Fertilization rate (%) 57.9 ± 2.8 46.09 ± 2.7 0.003* 20.19 to 3.389
No. of top-quality embryos 2.6 ± 0.23 2.0 ± 0.19 0.018* 1.19 to 0.047
Endometrial thickness on the day of embryo transfer (mm) 10.0 ± 0.32 10.2 ± 0.27 0.82 0.623 to 1.09
*Statistically significant, data presented as mean ± S.E.
Table 3. Controlled ovarian stimulation characteristics of pregnant and non-pregnant normo-responder patients in antagonist cycles.
Pregnant (n¼34) Non-pregnant (n¼49) p Value 95% CI
P on the hCG day pre-measurement (ng/ml) 1.37 ± 0.1 1.2 ± 0.09 0.13 0.45 to 0.11
P on the hCG day (ng/ml) 1.51 ± 0.09 1.38 ± 0.08 0.17 0.39 to 0.13
E2 on the hCG day (pg/ml) 2482.5 ± 1253.9 2263.5 ± 176 0.39 770.8 to 332.8
Number of retrieved oocytes 15.2 ± 1.2 14.1 ± 0.9 0.46 4.22 to 2.02
Number of MII oocytes 10.9 ± 0.9 9.9 ± 0.8 0.35 3.52 to 1.50
Fertilization rate 51.3 ± 3.9 47.8 ± 3.5 0.51 14.19 to 7.13
No. of top-quality embryos 3.05 ± 1.67 2.04 ± 0.2 0.007* 1.75 to 0.289
Endometrial thickness on the day of embryo transfer 10.7 ± 0.4 10.2 ± 0.3 0.35 1.43 to 0.46
*Statistically significant, data were presented as mean ± SE.
Table 2. Embryo transfer day 3 and day 5 outcomes in patients with and





Day 3 (n, %)
Clinical pregnancy rate 17/70 (24.3) 2/7 (28.6) 0.80
Day 5 (n, %)
Clinical pregnancy rate 48/103 (46.6) 9/21 (42.9) 0.75
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multiple assessments during the days preceding hCG. The
prospective study published by Kyrou et al. [22] revealed that
progesterone exposure during the ovarian hyperstimulation is
associated with a decreased probability of ongoing pregnancy.
However, hCG day progesterone level is not related to achieve-
ment of pregnancy. Rather than a single measurement, analysis of
the change in the last 48 h of the stimulation, as determined in our
study, could be a more informative option. More stable values of
progesterone observed in pregnant cycles during the last 48 h of
stimulation, which is different from the fluctuations observed in
non-pregnant cycles, could be another factor affecting the
outcomes.
The management of the patients who had progesteron eleva-
tion at the late follicular phase is still controversial. Some of the
authors revealed no negative impact of progesteron elevation on
the pregnancy rates in women performing blastocyst transfer,
whereas others did not demonstrated any improvement of
blastocyst transfer [23–26]. Another suggested management
option for these patients is freeze all policy. However, this
option mainly depends on the embryo quality of the patient and
laboratory equipment of the IVF center.
The main limitation of this study was its case-controlled
design. However, to the best of our knowledge, this is the first
study that demonstrates an effect of change in progesterone level
in the last 48 h of stimulation rather than a single level above the
determined threshold.
As a conclusion, although there are questions regarding the
effects of late follicular phase progesterone rise, the assessment
change in the last 48 h of the stimulation cycle may be more
informative than a single measurement. However, more studies
are needed to draw strong conclusions.
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